IN BRIEF (Page 19)
China Daily | Updated: 2010-10-13 08:09
Experimental drug shows promise
An experimental melanoma drug from GlaxoSmithKline has managed to shrink secondary tumors in the brains of nine patients with advanced disease, according to results of a small clinical trial.
The development is encouraging because secondary tumors, or metastases, in the brain are a major problem in the deadly form of skin cancer.
Photo
